Research focuses on preclinical neuropharmacology for seizure and neurodevelopmental disorders. Using genetic models, behavioral phenotyping and electrophysiology, Kaplan evaluates small‑molecule strategies to enhance inhibitory neurotransmission and translate findings toward therapies for Dravet syndrome and related pediatric epilepsies.